Private company
Galera Therapeutics, Inc.
American pharmaceutical preparations company based in Malvern.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $42.3M3 | $54.8M4 | $52.4M5 | $31.0M6 | $24.1M7 | $3.2M8 | $349.0K8 | |
| Operating income | -$50.7M3 | -$70.6M4 | -$73.4M5 | -$51.2M6 | -$49.3M7 | -$20.2M8 | -$2.5M8 | |
| Interest | $3.0M3 | $4.9M4 | $7.2M5 | $11.6M6 | $11.4M7 | $08 | $08 | |
| Income tax | -$9.0K3 | -$16.0K4 | $05 | $70.0K6 | $07 | -$203.0K8 | $08 | |
| Net income | -$51.9M3 | -$74.2M4 | -$80.5M5 | -$62.2M6 | -$59.1M7 | -$19.0M8 | $149.0M8 | |
| Earnings per share | -$1.337 | -$0.348 | $0.648 | |||||
| Earnings per share (diluted) | -$1.337 | -$0.348 | $0.648 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash | $18.4M3 | $15.9M4 | $19.9M5 | $4.3M6 | $18.3M7 | $8.3M8 | $6.4M8 | |
| Current assets | $117.6M3 | $77.9M4 | $77.4M5 | $38.5M6 | $21.6M7 | $10.0M8 | $7.1M8 | |
| Total assets | $123.4M3 | $84.1M4 | $83.3M5 | $44.0M6 | $26.1M7 | $10.1M8 | $7.2M8 | |
| Current liabilities | $9.7M3 | $14.0M4 | $12.9M5 | $13.4M6 | $5.0M7 | $1.7M8 | $645.0K8 | |
| Total liabilities | $53.8M3 | $78.0M4 | $141.3M5 | $153.2M6 | $157.3M7 | $153.8M8 | $645.0K8 | |
| Shareholders’ equity | $69.6M4 | $6.1M5 | -$58.0M6 | -$109.2M7 | -$131.2M8 | -$148.0M8 | $4.0M8 | |
| Shares outstanding | 24.8M shares3 | 25.0M shares4 | 26.5M shares5 | 28.5M shares6 | 54.4M shares7 | 75.5M shares8 | 75.5M shares8 | 75.5M shares8 |
Leadership
Who has led Galera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerMel Sorensen Nov 6, 2019 to now12
- PresidentMel Sorensen Nov 6, 2019 to now12
- Chief financial officerChris Degnan Nov 6, 2019 to Mar 14, 202313
- Chief operating officerRobert A. Beardsley Nov 6, 2019 to Feb 28, 202314
Board members and other officers (14)
- Chief Medical OfficerEugene P. Kennedy Sep 2, 2022 to Feb 28, 202315
- OfficerJennifer Evans Stacey Oct 12, 2021 to Feb 28, 202316
- Chief Commercial OfficerMark Bachleda Oct 12, 2021 to Mar 20, 202317
- Chief Scientific OfficerDennis Riley Feb 4, 2020 to Feb 4, 202018
- Chief Business OfficerArthur Fratamico Nov 6, 2019 to Jan 28, 202119
- Chief Accounting OfficerJoel F. Sussman Nov 6, 2019 to now20
- Chief Medical OfficerJon T. Holmlund Nov 6, 2019 to Mar 2, 202221
- Board memberNancy T. Chang Jan 2, 2025 to now22
- Board memberLinda West Apr 2, 2020 to Jul 5, 202323
- Board memberEmmett Cunningham Nov 6, 2019 to Jun 16, 202324
- Board memberJason Fuller Nov 6, 2019 to Nov 8, 201925
- Board memberKevin G. Lokay Nov 6, 2019 to now26
- Board memberLawrence M. Alleva Nov 6, 2019 to now27
- Board memberMel Sorensen Nov 6, 2019 to now12
Timeline
- Nov 6, 2019New chief executive Mel Sorensen becomes CEO12
Filings
211 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 56 major events, 67 insider forms, 30 large holders, 2 private raises, 37 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 7, 2026EFFECT EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 4, 202615-12G EDGAR
- Aug 4, 2026POS AM EDGAR
- Aug 4, 2026S-8 POS EDGAR
- Aug 4, 2026S-8 POS EDGAR
- Aug 4, 20268-K EDGAR
- Jul 31, 20268-K EDGAR
- Jul 13, 2026DEFA14C EDGAR
- Jul 13, 20268-K EDGAR
- Jul 7, 2026DEFA14C EDGAR
- Jul 7, 20268-K EDGAR
- Jul 2, 2026DEFM14C EDGAR
- Jun 11, 2026SCHEDULE 13D EDGAR
The 211 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 30 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Jun 11, 2026SCHEDULE 13D
- May 29, 2026SCHEDULE 13D/A
- Apr 27, 2026SCHEDULE 13D
- Apr 10, 2026SCHEDULE 13D
- Feb 14, 2025SCHEDULE 13G
- May 16, 2024SC 13G/A
- May 16, 2024SC 13G
- May 1, 2024SC 13G/A
- Apr 16, 2024SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARJennifer Evans Stacey, Officer
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARNancy T. Chang, Board member
- 23SEC EDGARLinda West, Board member
- 24SEC EDGAREmmett Cunningham, Board member
- 25SEC EDGARJason Fuller, Board member
- 26SEC EDGARKevin G. Lokay, Board member
- 27SEC EDGARLawrence M. Alleva, Board member